2020
DOI: 10.1016/j.ygyno.2019.12.031
|View full text |Cite
|
Sign up to set email alerts
|

High homogeneity of MMR deficiency in ovarian cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
49
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 31 publications
(52 citation statements)
references
References 40 publications
1
49
1
Order By: Relevance
“…Evaluation of the MMR status throughout all available cancer-containing tumor blocks revealed homogeneous MMR protein loss in all three NECs with confirmed MSI. This is in agreement with our previous observations of high homogeneity of MSI in prostate [36], ovarian [37], and bladder cancer (unpublished data). Overall, these data may suggest that MMR inactivation generally occurs early in tumorigenesis.…”
Section: Discussionsupporting
confidence: 94%
“…Evaluation of the MMR status throughout all available cancer-containing tumor blocks revealed homogeneous MMR protein loss in all three NECs with confirmed MSI. This is in agreement with our previous observations of high homogeneity of MSI in prostate [36], ovarian [37], and bladder cancer (unpublished data). Overall, these data may suggest that MMR inactivation generally occurs early in tumorigenesis.…”
Section: Discussionsupporting
confidence: 94%
“…This can be explained by zonal differences in the quality and extent of formalin fixation, which appears to be particularly common in the testis probably because the dense capsula albuginea hinders formalin penetration. In earlier TMA studies using identical IHC protocols for MMR protein evaluation in bladder, prostate, and ovarian cancer, we observed a lower rate of tumors demonstrating TMA-screening based MMR protein loss that could not be confirmed on large sections compared to the present study on testicular cancer (41)(42)(43).…”
Section: Discussioncontrasting
confidence: 87%
“…In a very recent study of 478 OvCs by Fraune et al, MMR deficiency occurred almost exclusively in endometrioid subtype (8 of 32) and also in one of 358 serous carcinomas. MMR of other subtypes (mucinous, clear cell, carcinosarcomas of Mullerian origin, and mixed carcinosarcomas) was functional [121]. Whereas all MMR-deficient endometrioid cancers were MSI and showed loss of MLH1/PMS2 proteins in five of 32 cases, MSH2/MSH6 in two of 32 cases, and isolated MSH6 in one of 32 cases; the MMR-deficient serous carcinoma was microsatellite stable and showed PMS2 protein loss and an altered pattern of MLH1 with putative partial MLH1 protein loss [121].…”
Section: Mismatch Repairmentioning
confidence: 96%